Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA

被引：12

作者：

Psimadas, Dimitrios ^{[1
]}

Valotassiou, Varvara ^{[1
]}

Alexiou, Sotiria ^{[1
]}

Tsougos, Ioannis ^{[1
]}

Georgoulias, Panagiotis ^{[1
]}

机构：

[1] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Nucl Med, Larisa, Greece

来源：

CANCER INVESTIGATION | 2018年 / 36卷 / 02期

关键词：

Antibodies; radiolabeling; PSMA; prostate cancer; LU-177-PSMA-617 RADIOLIGAND THERAPY; METASTATIC PROSTATE-CANCER; MEMBRANE ANTIGEN PSMA; MONOCLONAL-ANTIBODY J591; IN-VIVO; PRECLINICAL EVALUATION; EXTRACELLULAR DOMAIN; RADIATION-DOSIMETRY; INHIBITORS; TUMORS;

D O I：

10.1080/07357907.2018.1430816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).

引用

页码：118 / 128

页数：11

共 50 条

[1] Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
Abusalem, Mohammed
Martiniova, Lucia
Soebianto, Sarita
Depalatis, Louis
Ravizzini, Gregory
CANCERS, 2023, 15 (18)
[2] Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
Pillai, Maroor Raghavan Ambikalmajan
Nanabala, Raviteja
Joy, Ajith
Sasikumar, Arun
Knapp, Fum F.
NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (11) : 692 - 720
[3] The utility of radiolabeled PSMA ligands for tumor imaging
Shahrokhi, Pejman
Masteri Farahani, Arezou
Tamaddondar, Mohammad
Rezazadeh, Farzaneh
CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 99 (01) : 136 - 161
[4] Radiopharmaceuticals targeting PSMA for imaging and/or therapy
Morgat, C.
Gallerande, H. de Clermont
Fernandez, P.
Hindie, E.
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2019, 43 (03): : 284 - 286
[5] Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
Fung, Edward K.
Cheal, Sarah M.
Fareedy, Shoaib B.
Punzalan, Blesida
Beylergil, Volkan
Amir, Jawaria
Chalasani, Sandhya
Weber, Wolfgang A.
Spratt, Daniel E.
Veach, Darren R.
Bander, Neil H.
Larson, Steven M.
Zanzonico, Pat B.
Osborne, Joseph R.
EJNMMI RESEARCH, 2016, 6 : 1 - 10
[6] PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective
Debnath, Sashi
Zhou, Ning
McLaughlin, Mark
Rice, Samuel
Pillai, Anil K.
Hao, Guiyang
Sun, Xiankai
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[7] PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Lutje, Susanne
Heskamp, Sandra
Cornelissen, Alexander S.
Poeppel, Thorsten D.
van den Broek, Sebastiaan A. M. W.
Rosenbaum-Krumme, Sandra
Bockisch, Andreas
Gotthardt, Martin
Rijpkema, Mark
Boerman, Otto C.
THERANOSTICS, 2015, 5 (12): : 1388 - 1401
[8] PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
El Fakiri, Mohamed
Geis, Nicolas M.
Ayada, Nawal
Eder, Matthias
Eder, Ann-Christin
CANCERS, 2021, 13 (16)
[9] A low molecular weight PSMA-based fluorescent imaging agent for cancer
Chen, Ying
Dhara, Surajit
Banerjee, Sangeeta Ray
Byun, Youngjoo
Pullambhatla, Mrudula
Mease, Ronnie C.
Pomper, Martin G.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 390 (03) : 624 - 629
[10] Molecular imaging and therapy of cancer with radiolabeled nanoparticles
Hong, Hao
Zhang, Yin
Sun, Jiangtao
Cai, Weibo
NANO TODAY, 2009, 4 (05) : 399 - 413

← 1 2 3 4 5 →